Valuation: Caplin Point Laboratories Ltd

Market Cap 197B 2.06B 1.8B 1.66B 1.54B 2.91B 2.96B 19.86B 7.8B 96.81B 7.74B 7.57B 333B P/E 2026
17.9x
P/E 2027 * 27.6x
Enterprise Value 197B 2.06B 1.8B 1.66B 1.54B 2.91B 2.96B 19.86B 7.8B 96.81B 7.74B 7.57B 333B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.9x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.15%
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member - 31/01/2026
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+0.64%+14.41%+78.97% 48.69B
-2.01%-6.16%+65.56%+113.90% 36.38B
-0.76%-2.99%-3.75%+39.93% 12.19B
-1.69%-1.42%+16.85%+91.33% 12.04B
+0.29%+0.38%+31.49%+122.13% 9.04B
+0.75%-0.82%+18.53%+38.49% 7.09B
-1.13%-1.96%+46.51%-5.95% 7.06B
+0.22%+0.78%+3.13%+234.97% 6.75B
+5.45%-7.36%-17.51%+15.85% 6.1B
Average +0.07%-0.42%+19.47%+81.07% 16.15B
Weighted average by Cap. -0.65%+0.09%+26.85%+86.64%

Financials

2026 2027 *
Net sales 21.28B 223M 195M 180M 166M 315M 321M 2.15B 845M 10.48B 838M 819M 36.04B 24.88B 261M 228M 210M 194M 369M 375M 2.51B 988M 12.26B 979M 958M 42.14B
Net income 6.16B 64.61M 56.51M 52.13M 48.14M 91.35M 92.89M 623M 245M 3.04B 243M 237M 10.44B 7.13B 74.73M 65.37M 60.29M 55.69M 106M 107M 720M 283M 3.51B 281M 274M 12.07B
Net Debt - -
Logo Caplin Point Laboratories Ltd
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-